Copenhagen, Denmark—Of the new data to guide therapeutic decisions in the treatment of epidermal growth factor receptor (EGFR) mutation–positive non-small cell lung cancer (NSCLC), the most immediately relevant appear to be generated from a negative trial presented at the European Society for Medical Oncology (ESMO) 2016 Congress. In a new overall survival (OS) analysis from a trial that previously failed to associate the tyrosine kinase inhibitor (TKI) gefitinib with a